Overview
Migraine affects roughly 12 % of the global population and is three times more prevalent in women than men. The hallmark of a migraine attack is a throbbing or pulsating pain that typically localizes to one side of the head, though it can shift or become bilateral in later phases. The pain usually lasts 4 to 72 hours if untreated and is frequently accompanied by nausea, vomiting, photophobia (sensitivity to light), and phonophobia (sensitivity to sound). Many sufferers also report difficulty concentrating, known colloquially as “brain fog,” and a sense of dizziness or vertigo.In up to 30 % of individuals, a migraine begins with an aura—a transient neurological phenomenon that may include visual disturbances (flashing lights, zig‑zag lines, or blind spots), sensory changes (tingling or numbness), or language difficulties. Aura typically precedes the headache phase by 5 to 60 minutes and resolves before the pain peaks. While the exact mechanisms remain incompletely understood, current research points to a cascade of cortical spreading depression, trigeminovascular activation, and release of inflammatory neuropeptides such as calcitonin gene‑related peptide (CGRP).
Migraine is not merely a “bad headache.” It is a chronic, often disabling condition that can impair work, school, and social functioning. Early recognition, lifestyle modification, and appropriate pharmacologic therapy can dramatically reduce attack frequency and severity. However, anyone experiencing a new, severe, or rapidly changing headache pattern—especially with fever, neck stiffness, neurological deficits, or after head trauma—should seek immediate medical evaluation, as these may signal a more serious condition.
History/Background
Descriptions of migraine‑like symptoms appear in ancient Egyptian papyri (c. 1500 BCE) and the writings of Hippocrates, who used the term “hemicrania” to denote one‑sided head pain. The Greek physician Galen later linked headaches to “humoral” imbalances. In the 19th century, neurologist Robert Mayer coined the modern term “migraine” from the French migraine, itself derived from the Greek hemikrania (“half‑skull”). The first systematic classification emerged in the International Classification of Headache Disorders (ICHD) in 1988, providing diagnostic criteria still used today. Advances in neuroimaging during the late 20th century confirmed that migraine involves functional brain changes rather than structural lesions, reshaping it from a “vascular” to a “neurovascular” disorder.Key Information
- Epidemiology: Approximately 1 billion people worldwide experience migraine; prevalence peaks between ages 25‑45. - Triggers: Common precipitants include hormonal fluctuations, sleep deprivation, stress, certain foods (aged cheese, red wine), bright or flickering lights, and environmental changes. - Pathophysiology: Central to migraine is cortical spreading depression, followed by activation of the trigeminovascular system and release of CGRP, substance P, and neurokinin A, leading to vasodilation and inflammation of meningeal blood vessels. - Diagnostic Criteria (ICHD‑3): At least five attacks fulfilling duration (4‑72 h), unilateral location, pulsating quality, moderate‑to‑severe intensity, aggravation by routine activity, and at least one of nausea/vomiting, photophobia, or phonophobia. Aura requires reversible visual or sensory symptoms lasting 5‑60 minutes. - Acute Treatments: Over‑the‑counter NSAIDs, acetaminophen, and combination analgesics; prescription triptans (sumatriptan, rizatriptan) that target serotonin 5‑HT₁B/₁D receptors; newer gepants (ubrogepant) and ditans (lasmiditan) for patients who cannot tolerate triptans. - Preventive Therapies: Lifestyle optimization, magnesium or riboflavin supplementation, beta‑blockers (propranolol), anticonvulsants (topiramate, valproate), antidepressants (amitriptyline), and CGRP monoclonal antibodies (erenumab, fremanezumab). - Impact: Migraine is the second leading cause of disability worldwide (after low back pain) and contributes significantly to lost productivity and health‑care costs.When to seek professional care: If headaches are new, progressively worsening, accompanied by fever, stiff neck, visual loss, weakness, or occur after a head injury, urgent medical assessment is essential.
Significance
Migraine’s high prevalence and potential for chronic disability make it a public‑health priority. Understanding its neurobiological underpinnings has spurred the development of targeted therapies—most notably CGRP antagonists—that have transformed preventive care for patients previously refractory to traditional drugs. Moreover, migraine research has illuminated broader concepts of brain excitability, pain processing, and the interplay between genetics and environment, influencing fields from neurology to psychiatry.Socially, migraine awareness campaigns have reduced stigma, encouraging sufferers to seek help and employers to implement accommodations such as flexible lighting and quiet workspaces. Economically, effective treatment reduces absenteeism and improves quality of life, underscoring the importance of continued funding for migraine research and education.
